Endo to Acquire NuPathe for $2.85/Share in Cash

Endo Health Solutions ENDP today announced it has entered into a definitive agreement under which Endo will acquire NuPathe Inc. PATH for $2.85 per share in cash, or approximately $105 million.  In addition to the upfront cash payment, NuPathe shareholders will receive rights to receive additional cash payments of up to $3.15 per share if specified net sales of NuPathe's migraine treatment ZECUITY are achieved over time.  Endo expects meaningful cost synergies from the transaction, which is expected to be accretive to Endo's adjusted diluted earnings per share within the first 12 months of closing.  See full press release